Boehringer Ingelheim gets USFDA nod for Ofev capsules to treat lung disorder

Ofev capsule is aimed at slowing the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis, an autoimmune condition.

New Delhi: The U.S. Food and Drug Administration on Friday approved German drugmaker Boehringer Ingelheim's Ofev capsules for a rare lung disorder.

The drug is first FDA-approved treatment for this condition, the FDA said in a statement.

Also Read: Boehringer Ingelheim to restructure the executive board

The drug is aimed at slowing the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis, an autoimmune condition.

Ofev was originally approved in 2014 for adult patients with idiopathic pulmonary fibrosis, which is another interstitial lung condition.